Pershing Square Capital
View Older Stories View More Recent Stories
-
Valeant under pressure to beef up management as new board meets
-
Pershing Square's Fraidin Sends Letter to Valeant Pharma (VRX) Upon Joining Board
-
Form SC 13D/A Valeant Pharmaceuticals Filed by: Pershing Square Capital Management, L.P.
-
Valeant gives Pershing Square 1 board seat, adds 2 other directors
-
Valeant gives Pershing Square a seat on its board
-
Valeant Pharma (VRX) Announces Addition of Three Independent Directors
-
Valeant Pharmaceuticals Announces The Addition Of Three New Independent Directors To Its Board
-
After-Hours Stock Movers 03/08: (BUFF) (CISG) (AVAV) Higher; (STEM) (PLNT) (ZAGG) Lower (more...)
-
Valeant Pharma (VRX) Said in Talks to Add New Director; May Come from Ackman's Pershing Square
-
Valeant Pharma (VRX) in Talks to Add New Board Members, Considering Pershing Executive - DJ
-
Ackman's Pershing Square Holdings down 18.6 percent so far in 2016: investor
-
Form SC 13D/A Valeant Pharmaceuticals Filed by: Pershing Square Capital Management, L.P.
-
Ackman acknowledges mistakes in 2015, details changes in portfolio
-
U.S. hedge funds boast lower losses as markets tumble further
-
Pershing Square's Ackman Thinks Interim Valeant (VRX) CEO Schiller Will Do 'Outstanding Job'
-
Ackman's Pershing Square ends 2015 with 20.5 pct drop
-
Ackman's Pershing Square Sold Nearly 5M Shares of Valeant Pharma (VRX) for Tax Purposes
-
Form SC 13D/A Valeant Pharmaceuticals Filed by: Pershing Square Capital Management, L.P.
-
Pershing Square Won't Comment on Valeant Pharma (VRX) CEO Medical Leave News
-
Ackman's Pershing Square Having an Up Month in December
-
Valeant says can contain hit to dermatology, projects 2016 growth
-
Ackman tells investors that this year could be his firm's worst ever
-
Valeant Pharma (VRX) CEO Pearson Says Walgreens Deal 'More than Replaces' Philidor
-
Ackman plays big role in laying out Canadian Pacific rail deal
-
Bill Ackman 'has killed Pershing Square. Its over'- Hempton (VRX)
-
Ackman boosts stake in drugmaker Valeant
-
Pershing Square Capital Affirms Lifting Valeant Pharma (VRX) Stake to 9.9%
-
Market Wrap: Pfizer, Allergan Make it Offiical; Icahn Gets Active on Xerox; Existing Sales Slump in Oct.
-
Pershing Square Holdings, Ltd. Increases Position In Valeant Pharmaceuticals International
-
Ackman's Pershing Square Capital Raises Stake in Valeant Pharmaceuticals (VRX) to 9.9%
-
Ackman's Pershing Square Moves Stake in Valeant Pharma (VRX) to 9.9%
-
Pershing Square Capital Raises Stake in Valeant Pharma (VRX) to 9.9%
-
Form SC 13D/A Valeant Pharmaceuticals Filed by: Pershing Square Capital Management, L.P.
-
Hedge funds' favorite stocks lag broader market: Goldman data
-
Ackman's Pershing Square Holdings off 24.5 percent YTD
-
Norfolk Southern hostile to Canadian Pacific's $28.4 billion bid
-
Ackman's Pershing Square 13F Shows 43.37M Stake in Mondelez (MDLZ), Maintained Air Products (APD), Canadian Pacific (CP), Valeant (VRX)
-
Ackman's Pershing Square Down 2.8% MTD, 21.2% YTD
-
Valeant, Ackman must face U.S. insider trading lawsuit
-
Ackman says Valeant stock 'extraordinary bargain'
-
Ackman says Valeant likely to pay down debt in the next 18 months
-
Big bets on Valeant hit some hedge funds hard in October
-
Ackman, in email, says supports Valeant CEO Pearson
-
Ackman backs Valeant CEO as shares tumble to 2-1/2 year lows
-
Valeant's crisis fuels feud between Ackman and Australian fund manager Hempton
-
Bill Ackman's Pershing Square Down 19% YTD (VRX)
-
Top 10 News for 10/26 - 10/30: Valeant's Saga Continues Marching Along; Walgreens Boots Moves to Acquire Rival
-
Valeant Pharma (VRX) Trades Near Lows Heading Into Weekend
-
Valeant Pharmaceuticals (VRX) Bull-Bear Debate Rages
-
Ackman: Valeant's main problem is PR, not fraud

